GLAND.NS Balance Sheet
Gland Pharma Ltd.
Profit & Loss Balance Sheet Cash Flow
Balance Sheet · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-24 01:36
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Property, Plant and Equipment | ₹15.59 Bn | ₹35.41 Bn | ₹37.51 Bn | ₹40.52 Bn | PropertyPlantAndEquipment |
| Capital Work-in-Progress | ₹1.77 Bn | ₹2.38 Bn | ₹1.51 Bn | ₹3.42 Bn | CapitalWorkInProgress |
| Goodwill | ₹0.00 Bn | ₹2.42 Bn | ₹2.48 Bn | ₹2.94 Bn | Goodwill |
| Other Intangible Assets | ₹0.12 Bn | ₹1.12 Bn | ₹1.06 Bn | ₹1.09 Bn | OtherIntangibleAssets |
| Non-current Investments | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | NoncurrentInvestments |
| Other Non-current Assets | ₹1.29 Bn | ₹1.76 Bn | ₹1.35 Bn | N/A | OtherNoncurrentAssets |
| Total Non-current Assets | ₹18.77 Bn | ₹50.16 Bn | ₹44.42 Bn | ₹49.84 Bn | NoncurrentAssets |
| Inventories | ₹19.45 Bn | ₹16.55 Bn | ₹16.85 Bn | ₹17.44 Bn | Inventories |
| Trade Receivables | ₹8.71 Bn | ₹15.59 Bn | ₹15.17 Bn | ₹18.91 Bn | TradeReceivablesCurrent |
| Cash and Cash Equivalents | ₹19.09 Bn | ₹3.57 Bn | ₹25.56 Bn | ₹33.59 Bn | CashAndCashEquivalents |
| Current Investments | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | CurrentInvestments |
| Other Current Assets | ₹2.48 Bn | ₹3.40 Bn | ₹5.31 Bn | ₹4.59 Bn | OtherCurrentAssets |
| Total Current Assets | ₹69.01 Bn | ₹56.45 Bn | ₹67.83 Bn | ₹75.27 Bn | CurrentAssets |
| Total Assets | ₹87.78 Bn | ₹106.61 Bn | ₹112.25 Bn | ₹125.11 Bn | Assets |
| Equity Share Capital | ₹0.16 Bn | ₹0.16 Bn | ₹0.16 Bn | ₹0.16 Bn | EquityShareCapital |
| Other Equity | ₹79.42 Bn | ₹87.07 Bn | ₹91.34 Bn | ₹103.41 Bn | OtherEquity |
| Equity Attributable to Owners | ₹79.59 Bn | ₹87.24 Bn | ₹91.51 Bn | ₹103.58 Bn | EquityAttributableToOwnersOfParent |
| Non-controlling Interests | N/A | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | NonControllingInterest |
| Total Equity | ₹79.59 Bn | ₹87.24 Bn | ₹91.51 Bn | ₹103.58 Bn | Equity |
| Long-term Borrowings | ₹0.03 Bn | ₹1.07 Bn | ₹0.78 Bn | ₹0.70 Bn | BorrowingsNoncurrent |
| Total Non-current Liabilities | ₹0.90 Bn | ₹5.39 Bn | ₹5.09 Bn | ₹5.44 Bn | NoncurrentLiabilities |
| Short-term Borrowings | ₹0.01 Bn | ₹2.13 Bn | ₹1.92 Bn | ₹1.73 Bn | BorrowingsCurrent |
| Trade Payables | ₹5.87 Bn | ₹8.63 Bn | ₹8.20 Bn | ₹8.34 Bn | TradePayablesCurrent |
| Other Current Liabilities | ₹0.92 Bn | ₹1.85 Bn | ₹3.02 Bn | ₹3.18 Bn | OtherCurrentLiabilities |
| Total Current Liabilities | ₹7.29 Bn | ₹13.98 Bn | ₹15.65 Bn | ₹16.08 Bn | CurrentLiabilities |
| Total Equity and Liabilities | ₹87.78 Bn | ₹106.61 Bn | ₹112.25 Bn | ₹125.11 Bn | EquityAndLiabilities |
Every figure above is the exact value of the named XBRL element from GLAND.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).